
    
      This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the
      toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with
      lower-risk MDS who have failed prior treatment with an ESA. The study will be conducted in
      two parts, an initial Phase 1b dose escalation study followed by a dose expansion phase.
    
  